Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip 100
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Bayer AG

www.bayer.com

Latest From Bayer AG

Bookmark
  • Analysis

Bayer Still Confident Of Future Prospects Post-Xarelto

By Kevin Grogan

The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.

Cancer Business Strategies
Bookmark
  • News

Amazon Expands Consumer Health With Advantage Of Cutting Prices

By Eileen Francis
E-commerce giant expands consumer health footprint in past six months with launches of generic OTC drug product lines at prices in some cases significantly undercutting competitors.  Primary Health and SoundHealth OTC drugs range from a few dollars less to about half the cost of brand name equivalents.
Dietary Supplements Commercial
Bookmark
  • Analysis

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain

By Joseph Haas, Alex Shimmings, John Davis, Jessica Merrill, Jo Shorthouse and Eleanor Malone

Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.

Deals Business Strategies
Bookmark
  • News

Mereo Makes It Stateside With OncoMed Merger

By Kevin Grogan

The UK company, which postponed plans for a US offering in April, has taken the M&A route to secure a Nasdaq listing by combining with OncoMed.

M & A Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By